Clinical trials: Mineralocorticoid Resistant Hyperkalemia
Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction
Lokelma for RAAS Maximisation in CKD & Heart Failure.
Background: CKD in patients with heart failure (HF) is common and associated with poor prognosis. Despite evidence of benefit with Renin-Angiotensin-Aldosterone-System inhibitor (RAASi) agents, they are avoided due to fear of…
- Conditions
- Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction, Hyperkalemia, ACE Inhibitor Induced Hyperkalaemia
- Trial name
- LIFT (NCT05004363)
- Testing
- Lokelma Oral Product
- Where
- United Kingdom
- Volunteers
- 112 people
- Sponsor
- St George's, University of London